Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Investigators propose hyperspectral imaging analysis as a method to distinguish the efficacy of hormone-combined cyclophosphamide therapy for PMN, and classify sensitive and insensitive patients treated with hormone-combined cyclophosphamide regimen. A variety of machine learning models were used to prove that hyperspectral imaging technology could assist patients in selecting the optimal treatment plan, and further explore the predictive indicators of PMN treatment effect.
Renal puncture pathological sections from patients with nephropathy. ENVI Classic software was used to process the hyperspectral images and delineate the region of interest, and the one-dimensional spectral data of each pixel in each region were derived. Machine learning and deep learning methods were used to analyze the characteristics of hyperspectral data and classify them.
The data of the previous study came from the Department of Pathology and Nephrology of Qianfoshan Hospital in Shandong Province. Under the light microscope, electron microscope and immunofluorescence microscope, the pathological types of glomerular diseases in patients with proteinuria were identified. By scanning the corresponding patient's H&E stained pathological sections, the hyperspectral microscopic images were classified by machine learning and deep learning methods, and the classification accuracy was greater than 85%. It was concluded that hyperspectral imaging technology can be used as a non-invasive diagnostic method to predict treatment response.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CTX group in remission | The patients with idiopathic membranous nephropathy were divided into two groups: the group in remission and the group without remission after the application of cyclophosphamide. The pathological sections of the kidneys of the two groups were observed by microhyperspectral imaging system, and the differences between the two groups of patients under the spectrum were analyzed. |
| |
| CTX group without remission | The patients with idiopathic membranous nephropathy were divided into two groups: the group in remission and the group without remission after the application of cyclophosphamide. The pathological sections of the kidneys of the two groups were observed by microhyperspectral imaging system, and the differences between the two groups of patients under the spectrum were analyzed. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Microscopic hyperspectral imaging system | Device | CTX for idiopathic membranous nephropathy |
|
| Measure | Description | Time Frame |
|---|---|---|
| Microhyperspectral image of a transrenal specimen | The microscopic hyperspectral images could accurately distinguish the remission group from the remission group with an accuracy of more than 80% | 2023.3-2023.12 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with clinical manifestations of massive albuminuria and confirmed by renal biopsy as idiopathic membranous nephropathy.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Wang Zunsong, doctor | Contact | 18660190175 | wzsong3@163.com |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015433 | Glomerulonephritis, Membranous |
| ID | Term |
|---|---|
| D005921 | Glomerulonephritis |
| D009393 | Nephritis |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Renal aspiration biopsy pathology
| D052776 |
| Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |